Immunotherapy for patients with malignant melanoma and brain metastases
| Autor: | Line Thing Simonsen, Anne Mette Sjørslev Schmidt, Trine Heide Øllegaard, Inge Marie Svane, Lars Bastholt, Adam Andrzej Luczak, Henrik Schmidt |
|---|---|
| Jazyk: | dánština |
| Rok vydání: | 2019 |
| Zdroj: | Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2019, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Laeger, bind 181, V01190057 . < https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser > Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2019, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Læger, bind 181, nr. 24, V01190057 . < https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser > Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2020, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Laeger, bind 182, nr. 7, V01190057 . < http://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser > University of Copenhagen University of Southern Denmark |
| Popis: | Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|